国际肿瘤学杂志

国际肿瘤学杂志››2012,Vol. 39››Issue (5): 373-376.

• 综述 •上一篇下一篇

复发性小细胞肺癌治疗进展

邵岚，张沂平

  1. 杭州，浙江省肿瘤医院肿瘤内科
  • 出版日期:2012-05-08发布日期:2012-05-02
  • 通讯作者:张沂平，E-mail：zyp@medmail.com.cn E-mail:zyp@medmail.com.cn
  • 基金资助:

    浙江省医药卫生betway必威亚洲 基金资助项目（2007B025）;吴阶平医学基金项目（320.6750.11059、320.6750.11091）

Treatment of recurrent small cell lung cancer

SHAO Lan， ZHANG Yiping

  1. Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China
  • Online:2012-05-08Published:2012-05-02
  • Contact:ZHANG Yi-ping, E-mail: zyp@medmail.com.cn E-mail:zyp@medmail.com.cn

PDF

1963

被引次数

24

摘要：尽管小细胞肺癌患者初治敏感，但大多数会复发，二线治疗能明显缓解症状，带来生存获益。目前，拓扑替康是推荐的敏感型复发小细胞肺癌治疗的二线标准方案。最近，多项氨柔比星的研究显示了其良好的前景。遗憾的是，目前还没有有效的靶向药物被证实。

关键词:小细胞肺癌,复发,治疗

Abstract:Smallcell lung cancer (SCLC) relapses in the majority of patients, even though most patients respond to firstline therapy. Subsequent therapy can provide significant palliation and prolongation of survival for many patients. At present, topotecan is considered the standard secondline chemotherapy. Recently, amrubicin has also shown more favorable antitumor activity, and is the most promising at present. Unfortunately, targeted agents have failed to demonstrate effectiveness for SCLC.

Key words:Small cell lung cancer,Recurrence,Treatment